RECCE PHARMACEUTICALS LTD — Director's Dealing 2021

Jun 21, 2021

ASX Announcement

==> picture [416 x 93] intentionally omitted <==

Change of Director’s Interest Notices – James Graham (CEO) & Michele Diliza

Sydney Australia, 22 June 2021: Recce Pharmaceuticals Ltd ( ASX:RCE ) ( FSE:R9Q ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, provides a notice of change of interests in Director holdings.

The Company advises that Chief Executive Officer James Graham has purchased a further $50,000 shares on-market at $1.045 per share . Chief Scientific Officer Michele Dilizia disposed of 175,000 shares (held directly) to fund personal income tax obligations.

Person whose relevantinterest changed	Quantity On	Quantity Off	Ordinary Share Holding Post(22 June 2021)
James Graham (CEO)	47,850 shares	-	6,031,932 Shares
Michele Dilizia	-	175,000 shares	3,543,485 Shares

This announcement has been approved for release by Recce Pharmaceuticals Board

==> picture [552 x 64] intentionally omitted <==

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ( Company ) ACN 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

the director for the purposes of section	205G of the Corporations Act.
Name of Director	James Hamilton Bray Graham
Date of last notice	25 February 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving riseto the relevant interest.	Mr. James Graham <J Graham Family A/c>Bulleen Pty Ltd
Date of change	16 June 2021
No. of securities held prior tochange	Total ordinary shares held prior to change:5,984,082Direct Interest:1. 2,840,332 ordinary shares2. 389,712 Class B Performance Shares3. 2,250,000 Unlisted OptionsIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,493,750 ordinary shares2. 356,250 Class B Performance SharesBulleen Pty Ltd1. 650,000 ordinary shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Fully paid ordinary shares
Number acquired	47,850 fully paid ordinary shares
Number disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details andestimated valuation	$50,003.25
No. of securities held after change	Total ordinary shares held after change: 6,031,932Direct Interest:1. 2,840,332 ordinary shares2. 389,712 Class B Performance Shares3. 2,250,000 Unlisted OptionsIndirect Interest:Mr. James Graham <J Graham Family A/c>1. 2,493,750 ordinary shares2. 356,250 Class B Performance SharesBulleen Pty Ltd1. 697,850 ordinary shares
Nature of changeExample: on-market trade, off-market trade, exerciseof options, issue of securities under dividendreinvestment plan, participation in buy-back	On market purchase

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change	N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd ( Company ) ACN 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michele Keryn Dilizia
Date of last notice	25 February 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	N/A
Date of change	16 June 202117 June 202121 June 2021
No. of securities held prior to change	3,718,485 fully paid ordinary shares577,212 Class B Performance Shares1,500,000 Unlisted Options
Class	Fully paid ordinary shares
Number acquired	N/A
Number disposed	175,000 ordinary shares
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$178,238.77

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	3,543,485 fully paid ordinary shares577,212 Class B Performance Shares1,500,000 Unlisted Options
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	On market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior tochangeNote: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011